NO165540C - Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n,n-dimetyl-1-(1-(4-klorfenyl)cyklobutyl)-3-metylbutylamin-hydroklorid-monohydrat. - Google Patents

Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n,n-dimetyl-1-(1-(4-klorfenyl)cyklobutyl)-3-metylbutylamin-hydroklorid-monohydrat.

Info

Publication number
NO165540C
NO165540C NO865093A NO865093A NO165540C NO 165540 C NO165540 C NO 165540C NO 865093 A NO865093 A NO 865093A NO 865093 A NO865093 A NO 865093A NO 165540 C NO165540 C NO 165540C
Authority
NO
Norway
Prior art keywords
cyclobutyl
dimethyl
chlorphenyl
preparing
active compound
Prior art date
Application number
NO865093A
Other languages
English (en)
Norwegian (no)
Other versions
NO865093L (no
NO865093D0 (no
NO165540B (no
Inventor
James Edward Jeffery
Derek Whybrow
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO165540(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of NO865093D0 publication Critical patent/NO865093D0/no
Publication of NO865093L publication Critical patent/NO865093L/no
Publication of NO165540B publication Critical patent/NO165540B/no
Publication of NO165540C publication Critical patent/NO165540C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO865093A 1985-12-17 1986-12-16 Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n,n-dimetyl-1-(1-(4-klorfenyl)cyklobutyl)-3-metylbutylamin-hydroklorid-monohydrat. NO165540C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (4)

Publication Number Publication Date
NO865093D0 NO865093D0 (no) 1986-12-16
NO865093L NO865093L (no) 1987-06-18
NO165540B NO165540B (no) 1990-11-19
NO165540C true NO165540C (no) 1991-02-27

Family

ID=10589895

Family Applications (2)

Application Number Title Priority Date Filing Date
NO865093A NO165540C (no) 1985-12-17 1986-12-16 Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n,n-dimetyl-1-(1-(4-klorfenyl)cyklobutyl)-3-metylbutylamin-hydroklorid-monohydrat.
NO2005022C NO2005022I1 (no) 1985-12-17 2005-09-14 N-Dimetyl-1-(1-(4-klorfenyl)cyklobutylÜ-3-metylbutylamin (sibutramin hydroklorid)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2005022C NO2005022I1 (no) 1985-12-17 2005-09-14 N-Dimetyl-1-(1-(4-klorfenyl)cyklobutylÜ-3-metylbutylamin (sibutramin hydroklorid)

Country Status (34)

Country Link
US (2) US4929629A (cg-RX-API-DMAC7.html)
EP (1) EP0230742B1 (cg-RX-API-DMAC7.html)
JP (1) JPS62155240A (cg-RX-API-DMAC7.html)
KR (1) KR940008913B1 (cg-RX-API-DMAC7.html)
CN (1) CN1016245B (cg-RX-API-DMAC7.html)
AT (1) ATE56942T1 (cg-RX-API-DMAC7.html)
AU (1) AU601167B2 (cg-RX-API-DMAC7.html)
CA (1) CA1266278A (cg-RX-API-DMAC7.html)
CS (1) CS259545B2 (cg-RX-API-DMAC7.html)
DD (1) DD263050A5 (cg-RX-API-DMAC7.html)
DE (1) DE3674570D1 (cg-RX-API-DMAC7.html)
DK (1) DK170770B1 (cg-RX-API-DMAC7.html)
EG (1) EG17770A (cg-RX-API-DMAC7.html)
ES (1) ES2018163T4 (cg-RX-API-DMAC7.html)
FI (1) FI90413C (cg-RX-API-DMAC7.html)
GB (1) GB8531071D0 (cg-RX-API-DMAC7.html)
GE (1) GEP19970812B (cg-RX-API-DMAC7.html)
GR (1) GR3001069T3 (cg-RX-API-DMAC7.html)
HU (1) HU201901B (cg-RX-API-DMAC7.html)
IE (1) IE59429B1 (cg-RX-API-DMAC7.html)
IL (1) IL80934A (cg-RX-API-DMAC7.html)
IN (1) IN163129B (cg-RX-API-DMAC7.html)
LU (1) LU90865I2 (cg-RX-API-DMAC7.html)
MX (1) MX4684A (cg-RX-API-DMAC7.html)
NL (1) NL300065I1 (cg-RX-API-DMAC7.html)
NO (2) NO165540C (cg-RX-API-DMAC7.html)
NZ (1) NZ218578A (cg-RX-API-DMAC7.html)
PH (1) PH22481A (cg-RX-API-DMAC7.html)
PL (1) PL149519B1 (cg-RX-API-DMAC7.html)
PT (1) PT83958B (cg-RX-API-DMAC7.html)
SU (1) SU1443796A3 (cg-RX-API-DMAC7.html)
UA (1) UA7206A1 (cg-RX-API-DMAC7.html)
YU (1) YU46033B (cg-RX-API-DMAC7.html)
ZA (1) ZA869078B (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
AU4542993A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
HUP0105431A3 (en) * 1999-01-20 2003-05-28 Abbott Gmbh & Co Kg Use of phenylcyclobutylamine for preparation of compositions to aid smoking cessation
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
WO2000056315A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of pain
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
AU3757200A (en) 1999-03-19 2000-10-09 Knoll Gmbh Treatment of pulmonary hypertension
AU3894500A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
PL365463A1 (en) * 1999-03-19 2005-01-10 Knoll Gmbh Treatment of osteoarthritis
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
CZ298293B6 (cs) * 1999-03-19 2007-08-15 Abbott Gmbh & Co. Kg Léčivo pro léčení poruch spánku
WO2000056309A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
WO2000056311A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Control of metabolism
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
SK13372001A3 (sk) * 1999-03-19 2002-07-02 Knoll Gmbh Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
RU2290924C2 (ru) * 2002-10-05 2007-01-10 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
CN101098850B (zh) 2005-01-06 2010-09-15 Cj第一制糖株式会社 西布曲明的无机酸盐
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2402581T3 (es) * 2006-02-23 2013-05-06 Pfizer Limited Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP2010503709A (ja) 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008062276A2 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CN101795684A (zh) * 2007-04-09 2010-08-04 赛多斯有限责任公司 他汀类化合物与抗肥胖药的组合
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
MX2011001405A (es) * 2008-08-06 2011-03-21 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de mc4.
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
ES2527466T3 (es) 2010-07-06 2015-01-26 Astrazeneca Ab Agentes terapéuticos 976
SMT201800453T1 (it) 2010-11-04 2018-11-09 Albireo Ab Inibitori di ibat per il trattamento delle epatopatie
ES2586956T3 (es) 2010-11-08 2016-10-19 Albireo Ab Combinación farmacéutica que comprende un inhibidor de IBAT y un aglutinante de ácidos biliares
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
FI90413C (fi) 1994-02-10
NZ218578A (en) 1989-04-26
AU6644286A (en) 1987-06-18
GB8531071D0 (en) 1986-01-29
ES2018163T4 (es) 2012-06-14
CS930586A2 (en) 1988-02-15
JPH0144176B2 (cg-RX-API-DMAC7.html) 1989-09-26
PH22481A (en) 1988-09-12
FI865030L (fi) 1987-06-18
YU205086A (en) 1987-12-31
KR940008913B1 (ko) 1994-09-28
AU601167B2 (en) 1990-09-06
NO865093L (no) 1987-06-18
IL80934A (en) 1990-07-26
ES2018163B3 (es) 1991-04-01
DK585786A (da) 1987-06-18
FI865030A0 (fi) 1986-12-10
CS259545B2 (en) 1988-10-14
IE59429B1 (en) 1994-02-23
FI90413B (fi) 1993-10-29
CN86108547A (zh) 1987-08-19
CN1016245B (zh) 1992-04-15
CA1266278A (en) 1990-02-27
MX4684A (es) 1993-12-01
HUT45964A (en) 1988-09-28
DD263050A5 (de) 1988-12-21
NO2005022I1 (no) 2005-10-03
PL149519B1 (en) 1990-02-28
YU46033B (sh) 1992-12-21
DK585786D0 (da) 1986-12-05
JPS62155240A (ja) 1987-07-10
KR870005961A (ko) 1987-07-08
IE863102L (en) 1987-06-17
US4929629A (en) 1990-05-29
NO865093D0 (no) 1986-12-16
IN163129B (cg-RX-API-DMAC7.html) 1988-08-13
HU201901B (en) 1991-01-28
US5068440A (en) 1991-11-26
PL263020A1 (en) 1988-05-12
NO165540B (no) 1990-11-19
UA7206A1 (uk) 1995-06-30
EG17770A (en) 1991-03-30
NL300065I1 (nl) 2001-12-01
GR3001069T3 (en) 1992-03-20
LU90865I2 (fr) 2002-02-18
ATE56942T1 (de) 1990-10-15
DE3674570D1 (de) 1990-10-31
EP0230742A1 (en) 1987-08-05
DK170770B1 (da) 1996-01-15
EP0230742B1 (en) 1990-09-26
ZA869078B (en) 1987-07-29
GEP19970812B (en) 1997-02-10
PT83958A (en) 1987-01-01
SU1443796A3 (ru) 1988-12-07
PT83958B (pt) 1989-05-12

Similar Documents

Publication Publication Date Title
NO165540C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n,n-dimetyl-1-(1-(4-klorfenyl)cyklobutyl)-3-metylbutylamin-hydroklorid-monohydrat.
KR900701261A (ko) 비만증 치료방법
ATA84882A (de) Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut
GEP20063773B (en) Steroid Sulphatase Inhibitors
DE3464333D1 (en) Use of a salt of the acid n-acetyl (alpha, beta) aspartylglutamic for the manufacture of a drug having an anti-allergic activity for local administration
DE3361609D1 (en) New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
IT8448983A0 (it) Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
DK211489A (da) Farmaceutisk praeparat
GR3001862T3 (en) Pharmaceutical preparation for tinea pedis
FR2244481A1 (en) Oral treatment of diabetes - with a complex of glibenclamide and phenformin
DE3751597D1 (de) Verwendung von 15-Deoxyspergualin als Arzneimittel.
WO1987003590A1 (fr) Medicament pour le traitement des maladies du foie
ES2042715T3 (es) Remedio medico veterinario y humano que tiene una actividad antivirial y antitumoral que contiene 2,6-diamino-3-fenil-azo-piridina.
SE8702227D0 (sv) New use
ES329066A1 (es) Procedimiento para la obtencion de esteres del difenilo sustituidos basicamente.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: REDUCTIL KAPSEL, HARD 10MG REDUCTIL KAPSEL, HARD 15MG; NAT. REG. NO/DATE: 99/2894,99/2895 20021202; FIRST REG. NO/DATE: LI , IKS54770 19990113

Spc suppl protection certif: 2005022

Filing date: 20050914

MK1K Patent expired